Steven Polyak, MD
Gastroenterology · Iowa City, IANPI 1932141660
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,000 of the $4,873 with a category attached, or 61.6%. Pfizer accounts for 61.6% of it on its own, with 1 other manufacturer making up the rest.
Across 2 payments — averaging $2436.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$3K
- Janssen Scientific Affairs, LLC$2K
Across 282 payments — averaging $5284.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$422K
- Gilead$289K
- Takeda Pharmaceuticals U.S.A., Inc.$275K
- E.r. Squibb & Sons, L.L.C.$193K
- Pfizer$161K
- Teva Pharmaceuticals USA, Inc.$81K
- plus $69K from 2 others
What the payments were for
- Consulting fees$1,87338%
- Speaking & faculty fees$3,00062%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 1 | $3,000 |
| Janssen Scientific Affairs, LLC | 1 | $1,873 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,873 in reported general payments places this provider in the 85th percentile of 113 gastroenterology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 35 | $217,393 |
| Humira(Cf) PenAdalimumab | 12 | $78,087 |
| Azathioprine | 21 | $614 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 11 | $532 |
| Sulfasalazine | 11 | $325 |
| Omeprazole | 12 | $273 |
| Ciprofloxacin Hcl | 14 | $76 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Iowa City
- Maen MasadehIowa City$24K
- Ahamed KhalyfaIowa City$3K
- Randhir JesudossIowa City$3K
- Abdullah AbbasiIowa City$2K
- Gopala KoneruIowa City$2K
- Yehudith Assouline-DayanIowa City$1K
- Rohit NathaniIowa City$1K
- Rami El AbiadIowa City$1K
- Mohamad MokademIowa City$1K
- Rintaro HashimotoIowa City$945
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.